We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mitomycin-C and Vinblastine in Advanced Breast Cancer.
- Authors
Navarro, Matilde; Bellmunt, Joaquín; Balañá, Carmen; Colomer, Ramón; Jolis, Laura; del Campo, José M.
- Abstract
Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine. A response to treatment was observed in 11 of 34 evaluable patients (32.3%), with 3 complete remissions (8.8%) and 8 partial remissions (23.5%). The median duration of response was 185+ days. The 12-month survival was 78% for responders, 48% for patients with stable disease and 0% for patients with progressive disease. The toxicity was acceptable with 20 episodes of moderate myelosuppression (58.8%) and 2 cases with congestive heart failure that responded to medical treatment. The MMC-VBL combination is an active regime for advanced breast cancer previously treated with antracyclines. This combination may be regarded as a standard second-line treatment for this type of tumor. Copyright © 1989 S. Karger AG, Basel
- Publication
Oncology, 1989, Vol 46, Issue 3, p137
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000226702